Key Highlights
- The a2 Milk Company Limited (ASX:A2M, NZX:ATM) updated its China infant milk formula recovery and FY27 outlook at its Annual Meeting on 19 November 2026.
- Estimated China label offtake has recovered to about 50% of pre-supply chain disruption levels, up from about 40% in August 2026.
- For FY27 the company expects Revenue growth of mid single digits, with an underlying EBITDA Margin of about 15% and 1H27 materially lower.
- Total IMF sales are expected to be broadly similar to FY26, with revenue and EBITDA weighted to the second half.
The a2 Milk Company Limited (ASX:A2M, NZX:ATM) has provided an update on its China infant milk formula recovery and an updated FY27 outlook, presented at its Annual Meeting on 19 November 2026. The company says it was affected by shortfalls of China label IMF product in the fourth quarter of FY26, which led many existing users to switch to alternative brands, with effects expected to carry into FY27.
China IMF Recovery
The company says estimated China label offtake has recovered to about 50% of pre-disruption levels, up from about 40% in August 2026. English label IMF was also indirectly affected by a USA label IMF recall announced in May 2026. The company says it is focused on executing its China IMF recovery plan, with details in pages 13 and 14 of its Annual Meeting presentation.
Recovery is expected to be gradual over FY27, supported by two new China label product launches, an updated a2 Platinum product and pending resolution of China importation requirements affecting a2 Genesis. Marketing will increase, particularly in the first half of FY27.
Updated FY27 Outlook
The company now expects total IMF sales to be broadly similar to FY26. Revenue and EBITDA are expected to grow in FY27, supported by product innovation, new markets, momentum in Other Nutritionals and Liquid Milk, and improved profitability at a2 Pōkeno. Group revenue and EBITDA are expected to be materially weighted to 2H27.
Against FY26 on a continuing operations basis, the company expects revenue growth of mid single digits, with 1H27 revenue slightly below 1H26. Underlying EBITDA margin is expected to be about 15%, with 1H27 materially below 1H26.
Other Guidance and Risks
The company expects Depreciation and Amortisation of about $20 million, cash conversion of about 70% to 80% and Capital Expenditure of about $70 million. Underlying EBITDA excludes $15 million of one-off a2 Pōkeno transformation costs, which include about $5 million of integration costs and about $10 million related to the Platinum transition.
The company lists a range of risks, including the pace of China IMF recovery, competitive intensity, cross-border trade, foreign exchange, farmgate milk pricing, regulatory requirements and the Middle East conflict. A range of outcomes is possible depending on the rate of recovery.
Looking Ahead
The next key indicators are the China label recovery in FY27, the launch performance of the new products, and whether the second-half weighting of Earnings materialises as expected.

_11_19_2026_01_17_37_380778.jpg)




Please wait processing your request...